<DOC>
	<DOCNO>NCT02488616</DOCNO>
	<brief_summary>Closed-loop strategy compose three component : glucose sensor read glucose level , insulin pump infuse insulin dose mathematical algorithm decide required insulin dosage base sensor 's reading . A dual-hormone closed-loop strategy would regulate glucose level infusion two hormone : insulin glucagon . The main objective project compare efficacy single-hormone closed-loop strategy , dual-hormone closed-loop strategy sensor-augmented pump therapy regulate glucose level outpatient setting 5 consecutive day adult type 1 diabetes . The investigator hypothesize dual-hormone closed-loop strategy reduce time spend hypoglycemia compare single-hormone closed-loop strategy , turn effective sensor-augmented pump therapy reduce time spend hypoglycemia .</brief_summary>
	<brief_title>Closed-loop Control Glucose Levels ( Artificial Pancreas ) 5 Days Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males females ≥ 18 year old . 2 . Clinical diagnosis type 1 diabetes least one year . 3 . The subject insulin pump therapy least 3 month . 4 . HbA1c ≤ 10 % . 5 . Live area Montreal . 1 . Clinically significant nephropathy , neuropathy retinopathy judge investigator . 2 . Recent ( &lt; 6 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . History pheochromocytoma insulinoma ( glucagon could induce hormonal response tumor ) 4 . Beta‐blockers high dose base investigator 's evaluation dosage interference glucagon ( glucagon modify effect betablockers , mostly evident high dos ) 5 . Chronic indometacin treatment ( prevent glucagon effect liver thus ability raise glucose ) 6 . Warfarin chronic treatment INR monitoring evaluate ( increase risk bleed ) 7 . Anticholenergic drug ( risk interaction ) 8 . Pregnancy . 9 . Severe hypoglycemic episode within two week screen . 10 . Current use glucocorticoid medication ( except low stable dose inhaled steroid ) . 11 . Known suspect allergy trial product 12 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator . 13 . Anticipating significant change exercise regimen admission ( i.e . start stop organize sport ) . 14 . Treatments could interfere glucagon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Closed-loop system</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Insulin</keyword>
</DOC>